Blood Res.  2018 Sep;53(3):223-226. 10.5045/br.2018.53.3.223.

Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma

• Greenbaum
• Green DJ
• Holmberg L
• Gooley T
• Till BG
• Budde LE
• Rasmussen
• Press OW
• Gopal AK

• KMID: 2429322
• DOI: http://doi.org/10.5045/br.2018.53.3.223

Abstract

BACKGROUND
Bendamustine is a chemotherapeutic agent that has shown broad activity in patients with lymphoid malignancies. It contains both alkylating and nucleoside analog moieties, and thus, is not commonly used for stem cell mobilization due to concerns that it may adversely affect stem cell collection. Here we describe the lymphoma subset of a prospective, non-randomized phase II study of bendamustine, etoposide, and dexamethasone (BED) as a mobilization agent for lymphoid malignancies.
METHODS
This subset analysis includes diffuse large B-cell lymphoma (N=3), follicular lymphoma (N=1), primary mediastinal B-cell lymphoma (N=1), and NK/T-cell lymphoma (N=1). Patients received bendamustine (120 mg/m² IV d 1, 2), etoposide (200 mg/m² IV d 1-3), and dexamethasone (40 mg PO d 1-4) followed by filgrastim (10 mcg/kg/d sc. through collection).
RESULTS
We successfully collected stem cells from all patients, with a median of 7.9×10⁶/kg of body weight (range, 4.4 to 17.3×10⁶/kg) over a median of 1.5 days (range, 1 to 3) of apheresis. All patients who received transplants were engrafted using kinetics that were comparable to those of other mobilization regimens. Three non-hematologic significant adverse events were observed in one patient, and included bacterial sepsis (grade 3), tumor lysis syndrome (grade 3), and disease progression (grade 5).
CONCLUSION
For non-Hodgkin lymphoma, mobilization with bendamustine is safe and effective.

Keyword

Bendamustine; Stem cell mobilization; Non-Hodgkin lymphoma

MeSH Terms

Autografts*
Bendamustine Hydrochloride*
Blood Component Removal
Body Weight
Dexamethasone*
Disease Progression
Etoposide*
Filgrastim
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cells*
Humans
Kinetics
Lymphoma
Lymphoma, B-Cell
Lymphoma, Follicular
Lymphoma, Non-Hodgkin*
Prospective Studies
Sepsis
Stem Cells
Transplantation, Autologous*
Tumor Lysis Syndrome
Bendamustine Hydrochloride
Dexamethasone
Etoposide
Filgrastim

Reference

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333:1540–1545. PMID: 7477169.

2. Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol. 2011; 48:S12–S23. PMID: 21530768.

3. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14:309–317. PMID: 18172283.

4. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26:4473–4479. PMID: 18626004.

5. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013; 31:2103–2109. PMID: 23650408.

6. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011; 29:3559–3566. PMID: 21844497.

7. Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013; 31:104–110. PMID: 23109692.

8. Gac AC, Azar N, Daguindau E, et al. Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. Leuk Lymphoma. 2016; 57:1149–1153. PMID: 26879408.

9. Reiser M, Josting A, Draube A, et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant. 1999; 23:1223–1228. PMID: 10414907.

10. Green DJ, Bensinger WI, Holmberg L, et al. Bendamustine (Treanda®), etoposide and dexamethasone (BED) followed by GCSF effectively mobilizes autologous peripheral blood hematopoietic stem cells. Blood (ASH Annual Meeting Abstracts). 2012; 120(Suppl):abst 4126.

11. Green DJ, Bensinger WI, Holmberg LA, et al. Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2016; 51:1330–1336. PMID: 27214069.

12. Chen RW, Li H, Bernstein SH, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017; 176:759–769. PMID: 27992063.

13. Armand P, Redd R, Bsat J, et al. A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016; 173:89–95. PMID: 26729345.

14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25:579–586. PMID: 17242396.

15. Cowan AJ, Stevenson PA, Cassaday RD, et al. Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission. Biol Blood Marrow Transplant. 2016; 22:380–385. PMID: 26348890.

16. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004; 103:3684–3688. PMID: 14739217.

17. Fox CP, McMillan AK, Bishton MJ, Haynes AP, Russell NH. IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. Br J Haematol. 2008; 141:244–248. PMID: 18353164.